WILMINGTON, DE & CINCINNATI, OH — Incyte (NASDAQ: INCY) and Enable Injections have formed a strategic partnership to co-develop and commercialize targeted cancer therapies using Enable’s enFuse® On-Body Delivery System, a device designed to simplify drug administration and expand treatment options for patients.
The collaboration will initially focus on Incyte’s investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, INCA033989, for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF)—two rare blood cancers known as myeloproliferative neoplasms (MPNs). The agreement grants Incyte exclusive, worldwide rights to use Enable’s enFuse technology for its mutCALR program, with the possibility of expanding to other assets in its pipeline.
Under the deal, Enable will receive an upfront technology access fee, along with potential research and development milestones, commercial milestone payments, and compensation for clinical and commercial device supply.
“At Incyte, we are continually seeking new ways to enhance care and improve the overall treatment pathway for patients,” said Bill Meury, President and Chief Executive Officer of Incyte. “We’re looking forward to partnering with Enable and combining our expertise to make advanced treatments more accessible and less burdensome for patients, while maintaining the high standards of safety and efficacy patients and providers expect.”
The enFuse system enables the subcutaneous delivery of large-volume biologics and small-molecule drugs, allowing patients to self-administer treatments under the skin rather than through intravenous infusion. The approach supports more flexible site-of-care options and could help reduce treatment time and healthcare costs.
“Partnering with Incyte reflects our shared commitment to advancing patient care through innovation,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “This collaboration demonstrates the growing recognition of our enFuse technology as an advanced solution that is designed to deliver large volumes of medication subcutaneously and providing patients with treatment options that could offer greater comfort, independence and quality of life.”
Incyte’s focus on MPNs, including ET and MF, continues to position it as a leader in developing disease-modifying therapies for rare hematologic cancers, while Enable’s delivery system adds a new dimension—potentially bringing advanced cancer care closer to home.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.